ROLITAC XR 0.5mg price in UAE

Overview

Welcome to Dwaey, specifically on ROLITAC XR 0.5mg Prolonged Release H/G Capsule page.
This medicine contains an important and useful components, as it consists of Tacrolimus.
ROLITAC XR 0.5mg is available in the market in concentration 0.5 mg/capsule and in the form of Prolonged Release H/G Capsule.

HEXAL AG is the producer of ROLITAC XR 0.5mg and it is imported from GERMANY, The most popular alternatives of ROLITAC XR 0.5mg are listed downward .

Mode Of Action

Tacrolimus inhibits T-lymphocyte activation, although the exact mechanism of action unclear. Tacrolimus bind to cytosolic receptors known as immunophilins (i.e., cyclophilin and FK binding protein-12 [FKBP-12], respectively), forming complexes that inhibit the production of cytokines via the calcineurin pathway. Inhibition of calcineurin activity inhibits early activation of T-cells (ie.immunosuppresion results).

Indication

Atopic dermatitis
Allergic contact dermatitis
Severe eczema
Psoriasis
Alopecia areata
Pyoderma gangrenosum
Cutaneous lupus erythematosus
Dermatomyositis
Seborrheic dermatitis
Rosacea
Lichen Planus
Pemphigus Vulgaris
Vitiligo
Graft-Versus-Host Disease
Ichthyosis.

Precaution

Monitoring of blood trough serum concentrations to prevent organ rejection and to reduce drug-related toxicity. Topical: Used with caution on the face or neck, large areas of the body (not >50% of the total BSA), or areas of broken skin. Infections at the treatment site should be cleared prior to therapy. Delay use in patients with unknown cause of lymphadenopathy or acute infectious mononucleosis till resolution. Use in patients with Netherton's syndrome is not recommended. Pregnancy. Lactation: Not known whether tacrolimus is distributed in milk following topical administration to skin

Side Effects

>10% Burning sensation (43-58%)
Pruritus (41-46%)
Flu-like symptoms (23-31%)
Skin erythema (12-28%)
Headache (5-20%)

Contra indication

Tacrolimus ointment is contraindicated in patients with a history of hypersensitivity to Tacrolimus or any other component of the preparation.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased nephrotoxicity with ciclosporin, aminoglycosides, amphotericin B, cisplatin, NSAIDs, vancomycin, co-trimoxazole, aciclovir, ganciclovir. Increased risk of hyperkalemia with potassium-sparing diuretics. Increased plasma concentrations and toxicity with azole antifungals, calcium-channel blockers, cimetidine, danazol, HIV-protease inhibitors, macrolide antibacterials and metoclopramide. Antacids, rifampin, rifabutin, casofungin, phenytoin, phenobarbital and carbamazepine decrease tacrolimus plasma concentrations. Concurrent admin of sirolimus and tacrolimus decrease levels of both.